Key Drivers
- Strong Cash Flow
- Stable Margins
- Meaningful Leverage
AIAI Summary
DGX has shifted from a slow defensive diagnostics dividend name to a credible earnings-acceleration story driven by advanced testing and AI efficiency, but with the stock already rerated, upside now depends on clean execution, sustained cash conversion, and avoiding margin or pricing slippage.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Stable Margins
- •Meaningful Leverage
DGX delivers solid profitability and strong cash flow with stable margins and covered dividends, but leverage is meaningful and the stock looks expensive with limited balance-sheet cushion.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Support holding
- •Resistance test
DGX is in a clear last month uptrend with momentum intact near recent highs, but it remains somewhat stretched after a volatile rebound and needs a clean break above $216 to extend the move.
Sharp drop from $204.55 on 2026-06-09 to $193.58 on 2026-06-22 before the rebound
Sentiment & News
Key News Insights:
- •MRD approval
- •Growth momentum
- •Valuation caution
Quest Diagnostics showed strong operational and clinical momentum, highlighted by a new MRD test approval and fresh 52-week highs, but valuation and external risks remain a watchpoint.
This news is broadly supportive for Quest Diagnostics' outlook, but upside may be capped near-term if the stock remains expensive
Similar Companies in Healthcare
Other companies in the same sector with AI ratings